Back to News
Market Impact: 0.45
Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Pharvaris said its pivotal Phase 3 CHAPTER-3 study of deucrictibant extended-release tablets for preventing hereditary angioedema attacks met the primary endpoint and all secondary efficacy endpoints. The report provides no numerical efficacy results or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
PHVS0.80
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- MTY Food Group Inc Profit Retreats In Q3
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings